Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia.
Pozzato
G
G
Zorat
F
F
Nascimben
F
F
Comar
C
C
Kikic
F
F
Festini
G
G
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000592:standards / Q000633:toxicity; D001853:Bone Marrow / Q000473:pathology; D004341:Drug Evaluation; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D055728:Primary Myelofibrosis / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D013792:Thalidomide / Q000008:administration & dosage* / Q000592:standards / Q000633:toxicity
D020533:Angiogenesis Inhibitors; D013792:Thalidomide